Fisher & Paykel Healthcare holds the 200-day line, shares steady on NZX
25.06.2026 - 22:03:11 | ad-hoc-news.de
By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 22:02.
Fisher & Paykel Healthcare Corp Ltd (NZFAPE0001S2) stock trades near its 200-day moving average on the NZX after its recent fiscal 2025 earnings release. The New Zealand-based medical device maker remains a key regional peer to global respiratory-care players such as ResMed and Philips in the hospital and home-care segments, according to market commentary from Reuters.Reuters coverage of Fisher & Paykel Healthcare
Recent earnings frame the chart picture
On 27 May 2026 Fisher & Paykel Healthcare reported its results for the financial year ended 31 March 2026, disclosing operating revenue of around NZD 1.69 billion and net profit of approximately NZD 280 million, per the company's investor presentation.FY26 annual results presentation on FPH Investor Relations The company highlighted resilient demand for its hospital hardware and consumables and more normalized volumes in homecare interfaces compared with the pandemic period, which has fed into a more stable trading pattern for the shares in recent weeks.FPH FY26 annual results news release
The group reaffirmed its focus on expanding its installed base of hospital systems and growing mask penetration in homecare, while noting currency headwinds from the New Zealand dollar against the US dollar and euro, as described in the detailed results commentary.Fisher & Paykel Healthcare annual report information These operational details and guidance ranges provide important context for technical analysts reading the share price action around key moving averages.
Where the 200-day line sits
According to trading data from the NZX and chart services such as TradingView, Fisher & Paykel Healthcare shares have in recent sessions traded modestly above their 200-day moving average, which stands in the mid-NZD 20s per share, with daily volumes largely consistent with the three-month average.TradingView chart for FPH on NZX The shares also remain well above the lows seen during the COVID-related demand normalization period, but below the peaks reached when hospital respiratory equipment demand was unusually elevated.
Market commentators note that the stock's beta and volatility profile is typical for a New Zealand-listed healthcare equipment provider, with the price reacting clearly to earnings and guidance updates and tracking sector sentiment moves seen in names such as ResMed on the NYSE.NZX instrument page for Fisher & Paykel Healthcare For chart-focused investors, the 200-day line and prior support zones around the low-to-mid NZD 20s remain important technical reference points when assessing risk in the stock.
All news and analysis on Fisher & Paykel Healthcare shares
Track further company announcements, price data and analyst commentary on Fisher & Paykel Healthcare via the dedicated topic page and the firm's investor-relations channel.
The product behind the stock
Fisher & Paykel Healthcare generates most of its revenue from respiratory care and acute care medical devices, including its Optiflow nasal high flow therapy system and associated humidification hardware and consumables for hospital use.Optiflow high flow therapy product information The company also supplies sleep apnea masks and interfaces for homecare patients, which form an important recurring revenue stream alongside the installed base of hospital devices.
Where the stock trades today
Fisher & Paykel Healthcare shares trade on the NZX in Wellington, recently quoted around the mid-NZD 20s per share on 2026-06-25 in New Zealand dollars, according to the latest exchange data.
Fisher & Paykel Healthcare at a glance
- Company: Fisher & Paykel Healthcare Corp Ltd
- ISIN: NZFAPE0001S2
- WKN: 881720
- Ticker: FPH
- Trading venue: NZX
- Price (as of 2026-06-25, 20:00): 25.00 NZD
- Market cap: 14.0 billion NZD (as of 2026-06-25)
- Sector / industry: Healthcare equipment and supplies
- Index membership: S&P/NZX 50 Index
- Next earnings date: 2026-11-26
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
